Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GranStone Trial
2026-525608-85-00Phase 3Authorised
- Sponsor
- Capital Region of Denmark
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of empagliflozin, losartan and hydrochlorothiazide in chronic granulomatous disease (CGD), hypercalcemia, hypoparathyroidism and 2 more, sponsored by Capital Region of Denmark. Primary endpoint: Image verified new or increased nephrolithiasis or nephrocalcinosis. Planned start May 2026; status: authorised.
02
Drugs
empagliflozinlosartanhydrochlorothiazide
03
Conditions
chronic granulomatous disease (CGD)hypercalcemiahypoparathyroidismhypercalciurianephrolithiasis
Beyond the preview
Go deeper on 2026-525608-85-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525608-85-00.